Drug Profile
IP 112
Alternative Names: IP-112Latest Information Update: 23 Jul 2019
Price :
$50
*
At a glance
- Originator InnoPharma Inc
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Jul 2019 Discontinued - Preregistration for Cancer in USA (unspecified route)
- 08 Sep 2016 Preregistration is ongoing in USA (Innopharma pipeline, September 2016)
- 25 Sep 2014 InnoPharma Inc has been acquired by Pfizer